Midapex is committed to developing implantable or wearable neuromodulation treatment solutions for the digestive system, especially functional gastrointestinal diseases and metabolic diseases. At present, the company has international leading research level in neuromodulation and treatment of inflammatory bowel disease (IBD), type II diabetes and constipation, and has innovative products. Some products have obtained CFDA registration certificate, and many products have entered the clinical trial stage. Recently, Midapace announced the completion of tens of millions of A+ rounds of financing, exclusively invested by Wutongshu Capital. This round of financing is mainly used for the clinical, registration, production and sales of neuromodulation product lines.
This article is reproduced from: https://www.itjuzi.com/investevent/13316022
This site is for inclusion only, and the copyright belongs to the original author.